Clinical Trials
12 trialsNCT07164469 2026-06-05
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07524530 2026-06-05
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Not yet recruiting
NCT07624799 2026-06-03
PACIFIC
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT07598110 2026-05-20
FT-RIC-HAPLO
Institut Paoli-Calmettes
Phase 2 Not yet recruiting
NCT07593482 2026-05-18
FC-BALANCE
Swiss Cancer Institute
Phase 2 Not yet recruiting
NCT06954987 2026-05-13
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07569965 2026-05-06
FRONTIER
Miltenyi Biomedicine GmbH
Phase 2 Not yet recruiting
NCT07137481 2026-03-04
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT05565105 2026-03-03
CD34+ Transplants for Leukemia and Lymphoma
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT07441967 2026-03-02
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07025824 2025-09-03
RELEVANT
Technische Universität Dresden
Phase 2 Not yet recruiting
NCT05303727 2022-07-01
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting